ARCHIVES

Phase II Elotuzumab Study Demonstrates 33 Months PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Federal Funding: IOM Report Praises DOD Breast Cancer Research Program

August 15, 1997

Obituary: Joseph Burchenal, 93, A Leader In Cancer Drug Development at MSKCC.

March 17, 2006

NIH Revises Application Receipt Dates

November 22, 1985

Long-Term Results Find Cisplatin Improves Survival

May 25, 2007

June Panel Meeting Dropped

June 3, 1977

In Brief: Phil Amoruso Will Be The New NCI Executive Officer; DRCCA Board Okays CCN Extension

January 2, 1981